GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $6.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 115.05% from the stock’s current price.

Several other analysts have also issued reports on GOVX. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Wednesday, October 8th. Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, GeoVax Labs currently has a consensus rating of “Moderate Buy” and an average target price of $139.50.

GeoVax Labs Stock Performance

GOVX opened at $2.79 on Wednesday. GeoVax Labs has a 52-week low of $2.61 and a 52-week high of $57.00. The firm has a market cap of $3.35 million, a P/E ratio of -0.08 and a beta of 3.67. The business’s fifty day moving average is $7.09 and its 200-day moving average is $13.19.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($7.75) earnings per share for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. On average, research analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Several hedge funds have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in GeoVax Labs during the 1st quarter worth $27,000. Hudson Bay Capital Management LP bought a new stake in shares of GeoVax Labs during the third quarter worth about $47,000. Armistice Capital LLC bought a new stake in shares of GeoVax Labs during the third quarter worth about $253,000. Finally, Sabby Management LLC acquired a new position in shares of GeoVax Labs in the third quarter valued at approximately $313,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.